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Single-pulse transcranial magnetic
stimulation (sTMS) for the acute treatment
of migraine: evaluation of outcome data for
the UK post market pilot program
Ria Bhola1, Evelyn Kinsella1, Nicola Giffin2, Sue Lipscombe3, Fayyaz Ahmed4, Mark Weatherall5
and Peter J Goadsby6,7*
Abstract
Background: Single pulse transcranial magnetic stimulation (sTMS) is a novel treatment for acute migraine.
Previous randomised controlled data demonstrated that sTMS is effective and well tolerated in the treatment of
migraine with aura. The aim of the programme reported here was to evaluate patient responses in the setting of
routine clinical practice.
Methods: Migraine patients with and without aura treating with sTMS had an initial review (n = 426) and training
call, and then participated in telephone surveys at week six (n = 331) and week 12 during a 3-month treatment
period (n = 190).
Results: Of patients surveyed with 3 month data (n = 190; episodic, n = 59; chronic, n = 131), 62 % reported pain
relief, finding the device effective at reducing or alleviating migraine pain; in addition there was relief reported of
associated features: nausea- 52 %; photophobia- 55 %; and phonophobia- 53 %. At 3 months there was a reduction
in monthly headache days for episodic migraine, from 12 (median, 8–13 IQ range) to 9 (4–12) and for chronic migraine,
a reduction from 24 (median, 16–30 IQ range) to 16 (10–30). There were no serious or unanticipated adverse events.
Conclusion: sTMS may be a valuable addition to options for the treatment of both episodic and chronic migraine.
Background
Migraine is the most common cause of disability due to
a neurological disorder [1] on a worldwide basis [2]. Mi-
graine can be ameliorated in some patients by life-style
advice, and when troublesome, requires treatment of
both attacks and strategies to reduce attack frequency
with preventives [3]. While much has been determined
about the biology of migraine in recent times [4], and
the future is promising [5], much needs to be done for
the burden on patients and society that migraine brings.
A particular issue in migraine is that of side effects,
such as weight gain with many preventives [6], or
vascular issues with acute attack therapies [7], or
both, are driving a need for new effective and well tolerated
treatments.
Transcranial magnetic stimulation (TMS) was first
described in 1985 [8] and followed seminal work by
Merton, Morton and Marsden [9] who had used elec-
trical stimulation of the cortex to dissect questions
around the cortical influence on motor reflexes [9–11],
and had found the stimulus painful to subjects. sTMS is a
non-invasive, safe and painless method of activating the
human motor cortex [12]. TMS is based on the principle
of electromagnetic induction. A pulse of current passes
through a coil located within the device and when the
device is placed over a person’s head for a very short
duration, it aims to depolarise neurons rapidly within a
target area [13]. Given early suggestions of an effect of
sTMS in migraine with aura [14], single pulse TMS was
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studied in cortical spreading depression (CSD) in rat [15],
as CSD in rat is considered an excellent model of human
aura [16]. sTMS inhibits CSD in rat and cat [15]. It has no
effect on nociceptive trigeminocervical neurons [17], while
it certainly inhibits nociceptive trigeminothalamic neurons
[18, 19].
sTMS has been shown to be effective in acute mi-
graine treatment in patients with migraine with aura in a
sham-controlled study [20]. Moreover, it is well accepted
to be safe [21]. The device is CE-marked in Europe, so it
can be used in clinical practice. The SpringTMS device
was introduced to open clinical practice through the post-
market pilot program in the UK and migraine patients,
both with and without aura, were selected for this treat-
ment. The aim of this program was to assess the impact of
sTMS on migraine symptoms and treatment during an ini-
tial 3 month treatment period: assessing the effect on pain
severity, associated migraine symptoms, attack duration
and acute medication use. Patients prescribed treatment
from December 2012, were also asked to provide data on
disability (HIT-6). We report on the treatment outcomes
over a 3 year period, having presented interim outcomes
previously in an abbreviated form [22].
Methods
Twenty specialist headache clinics in the UK partici-
pated in the post market pilot program, which com-
menced in June 2011 following receipt of the CE mark
for the SpringTMS device. Five centres, the authors of
this report, contributed all but 60 patients.
The headache specialists selected patients in the clinic
who had previously found acute medications intolerable
(n = 89), ineffective or inadequately effective (n = 72), or
had a medical contraindication (n = 57), or some com-
bination of these, to established approaches.
Patients were included who had a diagnosis of episodic
migraine with or without aura (n = 59) or chronic migraine
(n = 131) [23]. Patients were excluded if their treating phys-
ician felt they were unsuitable, such as presence of metal in
the upper body or history of epilepsy.
There were no stipulations placed on patients to
change their use of medicines during the TMS treatment
period, for those who were also using medicines, except
that for the initial experience medication overuse [24]
was actively discouraged. Patients could continue on
preventives (n = 64). Thirty three patients used an anti-
convulsant (topiramate n = 17; gabapentin n = 8; valproate
n = 3; pregabalin n = 2; lamotrigine n = 2; topiramate and
valproate n = 1) with one stopping topiramate 25 mg dur-
ing the reporting period.
Patients had the option to discontinue device use at
any point if they wished.
The data were compiled and analysed with the object-
ive of carrying out a service evaluation that in UK
practice does not require Research Ethics Committee re-
view (http://www.hra-decisiontools.org.uk/research/).
Patient selection
As a non-drug treatment in a specialist clinic setting, sTMS
provided an alternative option for a patient group with
unmet needs. Throughout the pilot program, participating
clinicians selected sTMS specifically for patients with dis-
abling migraine who could not successfully use established
treatments for a variety of reasons.
 Lack of efficacy on current treatment.
 Poor tolerability for current acute or preventive
treatments.
 Medical conditions that rendered established
medications unsafe to use and where patients were
trying to conceive.
During the later months of the program patients with
medication overuse were included, using combination
(Triptan with NSAID ± paracetamol (acetaminophen);
n = 53), codeine (n = 12) or triptans (n = 22).
Device distribution
Following receipt of the doctor’s prescription, the port-
able device was delivered to the patient at home and
within a week, a headache specialist nurse (RB or EK)
made first contact with the patient. At the initial call,
the patients were advised how to treat, based on the
Medical Advisory Board (MAB) guidelines (Table 1).
Their typical migraine pattern was documented, in terms
of frequency, severity and duration of attacks.
Data collection
Following a telephone (RB, EK) review with collection of
historical baseline data over the previous 3 months, and
a training call at the start of treatment, telephone sur-
veys at weeks 6 and 12 were conducted during the treat-
ment period. The questionnaire data at week 12 was
anonymised and subsequently analysed. Upon comple-
tion, patients’ progress with treatment was reported back
to their prescribing doctor.
Treatment
To treat migraine symptoms, the device is switched on
and positioned on the occiput by the patient and the
pulse is delivered with the press of a button. The device
weighs 1.5 Kg with dimensions H: 81 mm; W: 220 mm;
D: 134 mm. A brief sound is heard as the pulse is deliv-
ered. A second pulse may be delivered if required. At
treatment, a single magnetic field pulse is delivered of
nominally 0.9 T [20], measured 1 cm from the device
surface, with a rise time of 180 μsec and a total pulse
length of less than 1 ms.
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Patients were advised to treat as the guideline (Table 1)
and to initiate early treatment where possible. They were
advised to place the device over the back of the head
(Fig. 1).
Patients commenced treatment by delivering two con-
secutive pulses (a double pulse), which they repeated
after a minimum interval of 15 minutes on treatment
days. A total number of 16 single pulses, or eight double
pulses, per treatment day could be used with the option
to use more if required during months two and three of
the treatment period.
They could treat on as many acute migraine days as
they wished.
Over time, some doctors advised patients with a fre-
quent migraine pattern to start with daily sTMS treat-
ment and review the effect of varying treatment patterns
to reach an optimum individual level.
Treatment in pregnancy
Three patients were prescribed sTMS during the second
trimester of their pregnancy. They each suffered disabling
migraine attacks during the first trimester and the attacks
continued into the second trimester. They had been treat-
ing with medications (paracetamol [acetaminophen] and
codeine) without benefit. They each treated as per the
guideline (Table 1).
Analysis
Data were compiled from the patient survey responses
into a spreadsheet (Excel 2010) in which summary mea-
sures were prepared. Our primary outcome measure was
the migraine day. A migraine day was defined as, any day
on which there was head pain of moderate or severe in-
tensity, pain scale four or more out of a zero to ten scale,
lasting at least 4 hours, and fulfilling current criteria [23].
Secondary measures included a migraine attack, defined
as a succession of migraine days terminated by a non-
migraine day, and a headache day, which was a day with
any headache of any severity for more than an hour.
Migraine days at 12 weeks was tested for normality
(Kolmogorov-Smirnov Z test). To explore features
that may be associated with a useful outcome for migraine
prevention a generalized linear model was used with mi-
graine days at 12 weeks as the dependent variable, co-
factors: sex, episodic or chronic migraine, aura presence or
absence, and covariates of age and baseline migraine days.
The link function was identity. Migraine days at 12 weeks
was compared to baseline using a Wilcoxon signed-rank
test. A 5 % level of significance was used to assess out-
comes (IBM SPSS Statistics 21).
Results
Patient characteristics
A total of 449 patients were prescribed sTMS of which
331 completed initial training and first survey at 6 weeks.
One hundred and ninety (42 %) used the device to treat
Table 1 Initiation strategy from Medical Advisory Board
• Initiate treatment as early as possible when patient first experiences symptoms of migraine, including pain and/or aura symptoms.
• Fill-out the headache diary immediately after treatment or at any time after the migraine attack subsides.
• Record all symptoms, triggers and medications used during each attack in a diary
• Increase the number of pulses delivered during an attack using the following systematic method as needed to improve pain and symptom relief.
To Begin:
• Encourage the patient to deliver 2 sequential pulses as early as possible at the beginning of the migraine attack.
• Continue with 2 pulses every 15 min for 1–2 h or until pain and symptoms resolve.
• Encourage patients to withhold using rescue medication for the first hour or two if possible.
Evaluate after the first month (3–4 attacks) - if needed increase the number of pulses delivered
• Encourage the patient to deliver 3 sequential pulses as early as possible at the beginning of the migraine attack.
• Continue with 3 pulses every 15 min for 1–2 h or until pain and symptoms resolve.
Evaluate again after the second month (3–4 attacks) - if needed increase the number of pulses delivered
• Encourage the patient to deliver 4 sequential pulses as early as possible at the beginning of the migraine attack.
• Continue with 4 pulses every 15 min for 1–2 h or until pain and symptoms resolve.
Fig. 1 Position of device for treatment
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migraine attacks for 3 months and completed all surveys
(Fig. 2). By the treating physician’s choice, 40 were not
available to us for any training or follow-up and without
data these are not further reported. These patients
returned their devices. Seventy-eight patients are
newly prescribed and have not yet completed surveys.
An additional 48 patients treated for 3 months but did
not complete all surveys. At the time of writing one
hundred and ninety (42 %, 140 females), aged 49 ± 13
(mean ± SD) completed questionnaires at the initial
contact, 6- and 12-week time points. The report here
focuses on the one hundred and ninety patients who
treated for 3 months for efficacy and reports adverse
events for all patients who have made any such reports
(Table 2).
Frequency of migraine days
Patients treated an average of 13 attacks each month,
with a baseline frequency of migraine days of 15 (median,
10–20 IQ range). This frequency was 11 [6, 16] at 6 weeks
and 8 [3, 13] at 12 weeks. The frequency at 12 weeks was
normally distributed (Z = 1.13, P = 0.16) and reduced com-
pared to the baseline (Z = 5.1, P < 0.001). The baseline
frequencies are set out in Table 3.
The migraine day outcome could be predicted by a
model including presence or absence of aura and baseline
frequency (χ25 = 93.8, P < 0.001). The 12 week frequency
was lower in patients with aura (χ2 = 8.1, P = 0.004). Sex,
age, or episodic versus chronic diagnosis did not predict
the outcome at 12 weeks.
Fig. 2 Patient disposition. *New patient- survey provided and no data at the time of the evaluation. **Data set for primary analysis
Table 2 Patient characteristics
Migraine features # of patients # of attacks treated
Migraine with aura 83 3802
Migraine without aura 107 5913
Of these:
Episodic 59 3470
Chronic 131 6245
Table 3 Migraines per month, pain severity and duration of
attack by number of patients in each grouping over the
reporting period
Migraine days/month Baseline 6 weeks 12 weeks
<5 8 11 27
5–9 19 35 33
10–14 35 42 45
15–20 56 36 32
21–25 14 12 9
26–30 58 52 44
Pain severitya Baseline 6 weeks 12 weeks
0 0 3 2
1–3 0 44 63
4–6 32 85 75
7–9 140 54 47
10 18 4 3
Duration in days Baseline 6 weeks 12 weeks
<1 34 66 84
1 55 55 48
2 34 30 27
3 41 24 20
4 19 7 3
>4 2 2 3
aPain severity – 0 to 10 scale
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Pain
Data on one hundred and ninety patients with reports
on pain were available. One hundred and eighteen
(62 %) patients reported the device was effective at redu-
cing or alleviating their migraine pain after 12-weeks use
in over 9000 attacks. At each survey, patients were asked
to rate their responses. They rated ‘Good’, ‘Very Good’
and’Excellent’ as effective pain relief and a treatment op-
tion they would want to continue using. Patients rating
the treatment ‘No Effect’ or ‘Fair’ (n = 42), did not find
benefit or adequate benefit to continue the treatment.
Associated symptoms
Of 190 patients reporting at 12 weeks, 174 provided data
on at least one associated symptoms- nausea, photophobia
or phonophobia. Sixteen reported they did not typically
have any associated symptoms. Of the 174 who had such
symptoms, 121 (64 %) reported an improvement, defined
in their own terms by asking, was there improvement.
Reduced attack duration
A reduction in the number of headache days per attack
was reported in 102 of 185 patients reporting duration
data at 12 weeks. The average reduction was a mean de-
crease from 2.2 days to 0.7 days per attack. Five of the
190 patients did not report duration data at 12 weeks.
A reduction in the number of headache days per attack
was reported in 112 (59 %) of 190 patients reporting dur-
ation data at 12 weeks (Fig. 3). Forty-eight patients (25 %)
reported no change in duration at 12 weeks.
Dosing schedules
On average patients reported optimal dosing for their
symptoms in the range from 10 to 12 pulses per treat-
ment day. The majority of patients, 101 (53 %), treated
with two sequential pulses separated by 15-minute inter-
vals, per treatment day. Eight patients preferred a single
pulse repeated at 15 min intervals as they derived ad-
equate benefit with this. During the second and third
months, 53 patients treated with 3 sequential pulses
separated by 15-minute intervals and 28 used 4 sequen-
tial pulses separated by 15-minute intervals per treat-
ment day.
Overall effect
Most patients (120 of 190) reported treating earlier
worked better. Patients were not specifically asked but at
least one half reported that when their attack was
aborted, they felt clearer and did not have lingering
‘mugginess’ and tiredness. Some described that feeling
the next day as ‘crystal clear’, which they would not typ-
ically experience at the end of an acute attack or when
using medications.
Disability: HIT-6 scoring
One hundred and thirty-nine patients provided pre-
treatment scores (66, 62–70; median and interquartile
range) and post- (61, 56–66) TMS HIT-6 scores. Of
those patients, 19 (14 %) reported no change, 20 (14 %)
reported a higher score post-TMS and 100 (72 %) reported
a lower score post-TMS. Nineteen (14 %) reported scores
below 50 points.
Medication use
One hundred and sixty four of one hundred and ninety
patients reported using acute medications for attacks at
baseline. Of these, 119 patients reported a reduction in
acute medication use, averaging (8.5 ± 7.7) days reduc-
tion in medication use.
Durability of response
Over the course of the 3 month treatment period, pa-
tients who found benefit at 6 weeks, maintained or saw
greater improvement by week twelve. At 6 weeks 55 %
(n = 106) of patients had had benefit and this rose to
62 % (n = 118) at 12 weeks.
Tolerability
sTMS was well tolerated. No serious adverse events were
reported. Thirty- eight of 190 (20 %) patients reported
transient light-headedness for up to 20 min after pulse
delivery. Nineteen reported side effects of either tinnitus,
dizziness or tingling over the back of the head at the site
of pulse delivery up to 30 min following stimulation.
Thirteen reported worsening of migraine symptoms.
One patient reported neck and upper shoulder pain that
lasted 2 weeks although it is not clear whether this was
related to sTMS treatment. The discontinuation rate was
55 % (n = 105): no benefit or inadequate benefit (n = 49),
Fig. 3 Change in attack duration plotted by patient. While 102
patients had a reduction, 75 had no change and eight had an
increase. Five patients did not report the data
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cost and lack of National Health Service coverage (n = 17),
inconvenient (n = 15), migraine improved or resolved
(n = 12), inadequate or incomplete trial (did not
change dose when suggested; n = 7), side effects (n = 2)
and none stated (n = 3).
Pregnancy
All three patients treated their attacks throughout the
pregnancy on a regular basis and reported benefit
(Table 4). A reduction in pain severity, shorter attack
duration and a reduction in severity of associated symp-
toms were reported. All three patients subsequently gave
birth without complication to healthy children, and con-
tinued to treat in the post-partum period. No adverse
effects were reported.
Discussion
The data presented from an open-label experience with
single pulse transcranial magnetic stimulation (sTMS) in
a specialist headache clinic setting are broadly consistent
with the randomised sham-control data that is available
[20]. sTMS seems effective and is well tolerated. The
open label data extends the treatment experience to pa-
tients with migraine without aura and chronic migraine,
doing so based on preclinical data [15, 19], and interest-
ingly the results seem broadly comparable. The data sug-
gest there is a cumulative effect, in that patients do
better the longer they are treated, that attacks are short-
ened, typically by about 1 day and that acute medication
use is reduced. From a functional viewpoint, disability
scores as recorded with HIT-6 are reduced. Importantly
there were no serious or unanticipated adverse events,
in keeping with the generally excellent tolerability of the
sTMS [21]. Taken together the data support the use of
sTMS in migraine.
During the majority of this pilot programme, patients
selected were typically those who could not use estab-
lished acute migraine medications due to intolerable side
effects, lack of efficacy or inadequate efficacy or they
had medical contraindications to the medicines. There-
fore, it was not an aim to look at the impact of sTMS on
their medication use and reliance on acute treatments.
However, as the programme evolved, patients were pre-
scribed sTMS who also used acute medications regularly.
This enabled an additional outcome where many pa-
tients reported a reduction in use of acute medicines.
This may reflect a combination of factors such as shorter
attack duration, reduced number of migraine days and
effective pain relief from sTMS. This is a potential
significant advantage for sTMS and requires further
exploration.
Over time, it also became important to measure the
impact of the benefit to patients [25]. An important goal
of any treatment is to improve the quality of life for the
sufferer. The impact of sTMS on alleviating migraine
symptoms also had a significant impact on levels of dis-
ability. Reduced attack duration resulted in fewer head-
ache days, less suffering and reduced migraine disability
as reflected in HIT-6 scores [26]; HIT-6 is known to be
sensitive to change [27]. Adherence to use is another
surrogate for effect, since patients tend in general to
abandon ineffective therapies. Patients responding to
sTMS maintained use, which likely reflects its utility.
There are few safe medication treatments for patients
during pregnancy and sTMS may be an option to con-
sider for this patient group [21]. The three patients who
Table 4 Patients treating during pregnancy
Patient 1 Patient 2 Patient 3
Age: 29. Episodic Migraine with Aura. Age: 30. Chronic Migraine without aura. Age: 32. Chronic Migraine without aura.
Pre-pregnancy migraine pattern: Pre-pregnancy migraine pattern: Pre-pregnancy migraine pattern:
Frequency: 12 days/month. Duration:
0.5–1 day.
Frequency: 10 days/month plus daily
background pain.
Frequency: 15 days/month. Duration:
1–2 days.
Treatment: Triptan and sleep. No effective treatment. Treatment: frovatriptan, Syndol
(paracetamol [acetaminopheno] +
codeine + doxylamine + caffeine)
and Naproxen, goes to bed.
During pregnancy: During pregnancy: During pregnancy:
Frequency: 2–4 days per week, Duration
of 2–3 days, severe and in bed. Estimated
90 % reduced ability to function.
16 days: acute attacks plus daily
background pain. Duration: 1 day.
Estimated 50 % reduced ability
to function.
Treatment: Dihydocodeine during the
early pregnancy with partial benefit.
Estimated 60 % reduced ability to function.
TMS response: 2 consecutive pulses repeated
after 15 min. Consistent reduced pain
severity and duration. Could return to function
and did not need to go to bed.
TMS response: 4 pulses per day (2 consecutive
pulses repeated after 15 min). Stopped attack
escalation and reduced the severity back down
to a mild tolerable level within 1–2 h. Associated
symptoms resolved or did not develop.
TMS response: a single pulse repeated
after 15–30 min; up to 4 pulses per attack.
Initially combined with dihydrocodeine.
Subsequently used sTMS only and could
abort the attack within an hour. Associated
symptoms rarely developed.
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treated during pregnancy demonstrated safety and effi-
cacy and derived adequate benefit, and may prove to be
an additional treatment option for this patient group.
We could not generalise these numbers to a blanket rec-
ommendation; suffice to say medical treatment of preg-
nant, disabled migraine sufferers is very challenging [28]
and any new, apparently safe approach needs very ser-
ious consideration. In this vein it probably worth consid-
ering the TMS load that is offered in the treatment of
depression with repetitive TMS (rTMS). A recent meta-
analysis lists a range of stimuli from 1 to 2 Hz for 2–5 s
with anywhere from 30 to 2,500 pulses per session for
between 4 and 20 sessions [29], which is compared in
sTMS to at most eight pulses in a day. Taken together
with the estimated field strength at the apex of the fun-
dus at term, which is about the same as three exposures
to a microwave oven, and is shorter [21], sTMS is worth
clinicians’ consideration.
Limitations
The study is an open-label patient experience without
randomisation or allocation by protocol based on the li-
censed safety of the device and the data that exist. We
sought to evaluate the device in practice. There will be a
component of the placebo effect which for acute treat-
ment would be between 10 and 25 %, depending on
whether there was moderate/severe or mild pain at base-
line. For a preventive treatment the placebo effect is
assumed to be more substantial, although recent data
suggests that may not be the case. The fact that the ef-
fect built up may be either a regression to the mean or a
true evolution of the treatment effect. The botulinum
toxin experience suggests that placebo can be seen over
many weeks. Data are certainly missing, as one would
expect from clinical practice, and this may have inflated
the outcomes. It was a major issue that a substantial
group could not be evaluated for logistic reasons of par-
ticipation, although since this was limited to one site,
the impact seems mitigated. Despite all the limitations,
the outcomes are generally positive and the therapy very
well tolerated.
Conclusions
The sTMS device has demonstrated safety, efficacy and
very good tolerability as an acute migraine treatment in
open clinic settings. Our recent analysis suggests there
may be a cost advantage to sTMS in the preventive set-
ting [30], and such factors need to be considered as
healthcare decisions are made going forward. It thus
provided an effective treatment option for patients who
could not treat, or treat adequately, with existing treat-
ments. Further clinical use is warranted and careful
follow-up will help determine its place in modern
therapy.
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